Anna Kazanchyan | Cardiovascular Innovation and Protecting High-Risk Patients
Anna Kazanchyan joins Executive Insights for Life Sciences Innovators to discuss cardiovascular innovation, kidney protection, clinical development strategy, and advancing therapies designed to improve outcomes for high-risk patients.
Prefer audio only? Listen to this episode on Spotify.
Episode Overview
In this episode, Anna Kazanchyan discusses how Saghmos Therapeutics is developing novel therapies aimed at preventing Major Adverse Cardiac and Kidney Events (MACKE) in high-risk patients undergoing percutaneous coronary intervention (PCI). The conversation explores the science behind the company’s lead candidate, ST-62516, as well as clinical development, regulatory strategy, and the challenges of bringing innovative cardiovascular therapies to market.
Key Themes
- Cardiovascular and kidney protection therapies
- Preventing Major Adverse Cardiac and Kidney Events (MACKE)
- Clinical development of ST-62516
- Regulatory strategy and pathways to approval
- Building biotechnology companies around high-impact therapies
- Commercialization and market exclusivity in life sciences
Why This Matters for Life Sciences Leaders
Cardiovascular and kidney complications remain significant challenges for high-risk patient populations, creating a need for therapies that can improve outcomes while reducing long-term healthcare burdens. The conversation highlights the scientific, clinical, and strategic considerations involved in developing innovative therapies, while providing insight into how biotechnology leaders navigate clinical trials, regulatory milestones, and commercialization planning.
Guest Link
More from Executive Insights
Explore more conversations with life sciences founders, CEOs, investors, and operators on the Executive Insights for Life Sciences Innovators podcast.
